Indivior loses key patent battle in USA over opioid use disorder therapy

Shares in London-listed Indivior (LSE: INDV) have plummeted after the firm lost a court battle in the USA aimed at stopping Dr Reddy's Laboratories (NSE: DRREDDY) from marketing a generic version of its opioid use disorder therapy Suboxone Film (buprenorphine/naloxone).

Indivior admitted that should a generic version now enter the market in 2018, the result would “most likely be a rapid and material loss of market share for Suboxone,” amounting to “up to 80% of its market share within a matter of months.”

The firm added that  “a material loss in market share in the USA would have a significant adverse impact on the company's revenues, profitability and cash flows.”